AIM Vaccine Co., Ltd (HKG: 6660), a biopharmaceutical company based in China, has announced the submission of pre-Investigational New Drug (pre-IND) filings to China’s National Medical Products Administration (NMPA) for two of its mRNA vaccine candidates. These candidates target the respiratory syncytial virus (RSV) and herpes zoster, respectively.
RSV infection is a leading cause of mortality among infants under one year of age and is a significant contributor to respiratory infections and fatalities in the elderly population in China. Currently, there is no RSV vaccine available in China, even though vaccines from GlaxoSmithKline and Pfizer are accessible in international markets.
Herpes zoster, also known as shingles, remains dormant in the body following initial infection. The herpes zoster vaccine is designed to prevent the reactivation of the virus by boosting specific T cell-mediated immune responses. AIM’s mRNA vaccine for herpes zoster is capable of effectively triggering T cell responses, eliminating the need for adjuvants, which is anticipated to enhance the vaccine’s safety profile. No equivalent product has been approved in China to date.- Flcube.com
